Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Exclusion Criteria

• •Presence of primary brain tumors or brain metastases.
• •Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.
• •Unwilling to undergo neuropsychological assessments necessary for the study.
• •Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.
• •History of or suspected hypersensitivity to riluzole or to any of its excipients.
• •Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.
• •Hepatic impairment as indicated by: AST and/or ALT ≥ 3 X upper limit normal (ULN).
• •Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.